Thalia Therapeutics (LON:THAT – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported GBX (0.09) EPS for the quarter, Digital Look Earnings reports.
Thalia Therapeutics Stock Performance
LON THAT opened at GBX 0.61 on Wednesday. Thalia Therapeutics has a twelve month low of GBX 0.40 and a twelve month high of GBX 0.95. The company has a market cap of £10.89 million and a price-to-earnings ratio of -3.61.
Thalia Therapeutics Company Profile
RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.
Further Reading
- Five stocks we like better than Thalia Therapeutics
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
Receive News & Ratings for Thalia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thalia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
